IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Infinium Pharmachem IPO is a book build IPO listing on NSE EMERGE exchange. The company is based in Anand and caters to Pharmaceutical sector. Swastika Investmart is the merchant banker of Infinium Pharmachem IPO. It is a SME IPO which filed its Draft Red Herring Prospectus (DRHP) on 17th February 2023.
Infinium Pharmachem IPO posted revenues of Rs 159.70 crores and PAT of Rs 11.02 crores in FY23 on annualised basis.Financial results of Infinium Pharmachem IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
Infinium Pharmachem IPO PAT Margin is 8.57%, ROCE (Return on Capital Employed) is 56.81% as per latest financial. The below table shows Infinium Pharmachem IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
The market Capitalisation of Infinium Pharmachem IPO is Rs 93.93 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Infinium Pharmachem IPO prospectus highlights an Return on Equity (ROE) of 15%, Return on Assets (ROA) of 12%, and an EBITDA Margin of 18%, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Infinium Pharmachem IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Infinium Pharmachem IPO is ₹93.93 Cr, based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Infinium Pharmachem IPO has a Price-to-Earnings (PE) ratio of 7.83 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Infinium Pharmachem IPO reported revenue of ₹159.70 Cr in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Infinium Pharmachem IPO provide insights into sales growth, market demand, and business scalability.
Infinium Pharmachem recorded an EBITDA of ₹ 16.14 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Infinium Pharmachem Profit After Tax (PAT) is ₹9.98 Cr, reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 116.40 Cr.
EBITDA Margin:
13.87
%
Net Worth: ₹ 18.56 Cr.
Market Capitalisation:
₹ 93.93 Cr.
P/E:
7.83 times
P/BV: 2.14 times
EV/EBITDA: 6.52 times
Infinium Pharmachem operates in Pharmaceutical and Pharmaceutical & Healthcare Provider. The Issue is listed on NSE EMERGE in Apr, 2023. Infinium Pharmachem IPO size was 25.26 with Issue price of 135.00 .
Merchant Banker(s) of Infinium Pharmachem IPO: Swastika Investmart Limited
Infinium Pharmachem IPO subscription was 1.84 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Infinium Pharmachem IPO listed at a listing price of 141.50 against the offer price of 135.00.
The current market price of Infinium Pharmachem is 236.50.
Why Us?
